The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 403-408

  Ishihara, Yoko ^a   Matsunaga, Kenichi ^b   Iijima, Hiroko ^b   Hasegawa, Go ^a   Suzuki, Oshimitsu ^c   Sato, Atsushi ^d   Kobayashi, Tomowo ^e   Yang, Meng ^f   Hoffman, Robert M ^f,g  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUREHA CORPORATION   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY HOSPITAL   (Japan)

^e Foundation for Drug Discovery   (Japan)

^f ANTICANCER INC   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Colon cancer; FOLFIRI; GFP imaging; Orthotopic model; Survival time; Tumor growth metastasis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GREEN FLUORESCENT PROTEIN; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; LIVER METASTASIS; MESENTERY LYMPH NODE; METASTASIS INHIBITION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUOROURACIL; GREEN FLUORESCENT PROTEINS; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MICE; MICE, NUDE; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950536359     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Marshall JL and Gehan EA: The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the future. Clin Adv Hematol Oncol 5: 167-172, 2007.
2. Chung KY and Saltz LB: Adjuvant therapy of colon cancer: current status and future directions. Cancer J 13(3): 192-197, 2007.
3. Douilland JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000.
4. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
5. Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM and Peters GJ: 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 15: 1025-1032, 2004.
6. Morgan RG: Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer 63(6 Suppl): 1008-1012, 1989.
7. Wallin A, Svanvik J, Holmlund B, Ferreud L and Sun XF: Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep 19(6): 1493-1498, 2008.
8. Tschmelitsch J, Barendswaard E, Williams C Jr, Yao TJ, Cohen AM, Old LJ and Welt S: Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 57: 2181-2186, 1997.
9. Behr TM, Blumenthal RD, Memtsoudis S, Sharkey RM, Gratz S, Becker W and Goldenberg DM: Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 6: 4900-4907, 2000.
10. Yamamoto N, Jiang P, Yang M, Xu M, Yamauchi K, Tsuchiya H, Tomita K, Wahl GM, Moossa AR and Hoffman RM: Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res 64: 4251-4256, 2004.
11. Yang M, Jiang P and Hoffman RM: Whole-body subcellular multicolor imaging of tumor-host interaction and drug response in real time. Cancer Res 67: 5195-5200, 2007.
12. Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Investigational New Drugs 17: 343-359, 1999.
13. Yang M, Reynoso J, Bouvet M and Hoffman RM: A transgenic red fluorescent protein-expressing nude mouse for color-coded imaging of the tumor microenvironment. J Cell Biochem 106: 279-284, 2009.
14. Shimosato Y, Oboshi S and Baba K: Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1: 19-35, 1971.
15. Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, and Miyake H: Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 11: 3773-3777, 2005.
16. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, Wakiyama S, Fujita H, Shirouzu K and Mori M: Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92: 1754-1758, 2005.
17. Rajput A, Dominguez San Martin I, Rose R, Beko A, Levea C, Sharratt E, Mazurchuk R, Hoffman RM, Brattain MG and Wang J: Characterization of HCT116 human colon cancer cells in an orthotopic model. J Surg Res 147: 276-281, 2008.
18. Inoue Y, Tanaka K, Hiro J, Yoshiyama S, Toiyama Y, Eguchi T, Miki C and Kusunoki M: In vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. Int J Oncol 28: 479-486, 2006.
19. Cao S and Rustum YM: Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60: 3717-3721, 2000.
20. Ishizu K, Sunose N, Yamazaki K, Tsuruo T, Sadahiro S, Makuuchi H and Yamori T: Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull 30: 1779-1783, 2007.
21. Ji Y, Hayashi K, Amoh Y, Tsuji K, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M and Hoffman RM: The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res 27: 713-718, 2007.
22. Hoffman RM: The multiple uses of fluorescent proteins to visualize cancer in vivo. Nature Rev Cancer 5: 796-806, 2005.
23. Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP, Theodorescu D, Thompson EW and Welch DR: Preclinical drug development must consider the impact on metastasis. Clin Cancer Res 15: 4529-4530, 2009.